Showa Denko KK announces partnership with BIA Separations

SDK is investing in BIASep in order to enter the biopharmaceuticals resins market.

Showa Denko KK (SDK) has entered into a strategic partnership agreement with BIA Separations (BIASep), a purification technology firm based in Austria.

The partnership will enable the Japanese chemical engineering company to enter the biopharmaceutical resins sector and includes joint marketing and research & development.

In a statement, SDK said that through its strategic partnership with BIASep, it expects to achieve "good synergistic effect in terms of both technology and product mix".

"The market is expected to grow rapidly with the expansion of the biopharmaceutical industry," the company noted.

"SDK will fully utilise the technologies it has amassed through the Shodex business to enhance the synergies."
SDK's Shodex brand consists of a wide variety of analytical high-performance liquid chromatography (HPLC) columns which are delivered to customers around the world and are used to analyse compounds in areas such as medicine and organic chemistry analysis.

BIASep's CIM Monoliths technology enables more efficient purification of viral particles and large biomolecules, helping to bring down biopharmaceutical companies' production costs.